BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioMimetic Therapeutics, Inc. (BMTI) Slashes 25% of Workforce


1/24/2012 8:46:03 AM

Nashville Business Journal by Chris Silva, Staff Reporter

BioMimetic Therapeutics Inc. (Nasdaq: BMTI) has cut a quarter of its workforce in an effort to retain cash as it continues to work toward approval of its bone graft device, Augment, from the Food and Drug Administration.

BioMimetic, which has 75 employees, revealed the reductions in a Jan. 20 filing with the Securities and Exchange Commission. The company said the move would generate annual savings of approximately $2.5 million, primarily from savings in employee salaries and benefits.

BioMimetic also said a decision was made to “scale back” clinical program work on Augment as it continues to work with the FDA.

The Nashville-based biotechnology company was dealt a setback earlier this month when the FDA said a final decision on its premarket approval application for Augment was being delayed.

Augment is BioMimetic’s flagship product, and while it has gained approval for use in Canada and Australia, the potentially lucrative U.S. market has eluded the company. BioMimetic had hoped for FDA approval of Augment by the end of 2011.

In the SEC filing, BioMimetic said, “Given the company’s desire … (to) conserve resources until there is further clarity from the FDA regarding Augment, the company has decided to scale back the progress of its Augment injectable bone graft clinical program.”

BioMimetic now hopes to see Augment approved 15 to 24 months from now, as we recently explored for print subscribers, and still stands by that time frame.

"While awaiting the final response from the FDA ... we thoroughly assessed our cost structure and made the difficult decision to reduce our workforce and certain other expenditures," said Kearstin Patterson, a BioMimetic spokesperson, in an email. "While this type of action is always difficult, we believe it will provide us with the best opportunity for long-term success and establishes the best foundation for building stockholder value. We remain dedicated to prudently managing our financial resources while we’re working with the FDA to gain approval of Augment."




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES